Long-term course of ambulatory patients with COVID-19 initially treated with enoxaparin vs no anticoagulation: final analysis of the OVID (enoxaparin for outpatients with COVID-19) randomized trial.
Fumagalli RM, Voci D, Bikdeli B, Bingisser R, Colucci G, Forgo G, Gerardi T, Gerber B, Grigorean A, Klok FA, Righini M, Robert-Ebadi H, Stortecky S, Ulrich S, Wolf S, Wyss D, Hobohm L, Kucher N, Barco S; OVID investigators.
Fumagalli RM, et al. Among authors: gerardi t.
Res Pract Thromb Haemost. 2024 Jul 26;8(5):102534. doi: 10.1016/j.rpth.2024.102534. eCollection 2024 Jul.
Res Pract Thromb Haemost. 2024.
PMID: 39252826
Free PMC article.